Commonwealth Diagnostics International Inc., (CDI), was founded on the patient-centric principle that early detection and diagnosis of functional gastrointestinal disorders result in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system. Operating out of a newly constructed, state-of-the-art laboratory located in Salem, Massachusetts, CDI is an international diagnostic service provider specializing in innovative diagnostic products that assist physicians and patients in diagnosing and managing some of the most common sources of digestive distress and functional gastrointestinal ailments in the world. Their product portfolio includes, but is not limited to: hydrogen and methane breath testing for Small Intestinal Bacterial Overgrowth (SIBO), Lactose Malabsorption, Fructose Malabsorption, Sucrose Malabsorption; Urea Breath Test for H. Pylori; IBSchek™, a proprietary ELISA based blood test for IBS-D/M; and AbStats™, an easy-to-use, non-invasive, and gastrointestinal telemetry and sensory system. 

They take great satisfaction in commercializing specialist diagnostic technologies and integrating them with practical approaches that improve accessibility and ease of use for both patients and healthcare professionals. Instead of using pricey, invasive, and difficult-to-access diagnostic techniques, CDI offers non-invasive and affordable tools to produce crucial clinical data that aid healthcare professionals in making diagnoses and treatment decisions and empowers patients by giving them useful knowledge about their condition. CDI’s breath test options may be used in the patient’s home, reducing scheduling hassles for clients, lowering overhead expenses for practitioners, and freeing up key resources for all parties. CDI is an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose common sources of digestive distress and functional gastrointestinal ailments. A cost-effective array of diagnostic solutions, which is centered on our patient-centric principles, leads to quicker treatment, improved patient outcomes, and significant cost savings for the healthcare delivery system. Our broad range of products and services includes IBSchek, a proprietary capillary collection test for irritable bowel syndrome  (IBS-D/M), non-invasive at-home breath testing kits for Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methanogen Overgrowth (IMO), and carbohydrate malabsorption disorders, and MyGi Health, a cloud-based healthcare platform that enables patients to manage and comprehend their symptoms for a variety of conditions. As an FDA-registered, ISO 13485-accredited medical device manufacturer working out of a CLIA-approved lab, we take great satisfaction in our associations with top health systems, hospitals, and private clinics across the world.

One of the diagnostic solutions offered is Breath Testing for SIBO & IMO. Small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth can be diagnosed with the help of this breath test (IMO). The digestive tract may produce excessive hydrogen and/or methane gas when bacteria typically found in the large intestine are present in the small intestine. This can result in a variety of gastrointestinal symptoms, including bloating, diarrhea, and/or constipation. Small intestinal bacterial overgrowth (SIBO) has historically been used to identify this illness, and it has been divided into two categories: hydrogen-related SIBO and methane-related SIBO. Since methane in the gastrointestinal system is created by archaea, which are not bacteria, revised rules defining the differences between each categorization have led to the reclassification of methane-related SIBO as Intestinal Methanogen Overgrowth (IMO). The Hydrogen and Methane Breath Test for SIBO & IMO can be ordered with either a lactulose or glucose substrate. Pediatric kits are also available.

Breath Testing for Lactose Malabsorption a disease known as lactose malabsorption may happen when the enzyme required to break down lactose, a sugar frequently found in dairy products, is absent. Because the enzyme is absent, bacteria that are normally prevalent in your digestive tract can produce hydrogen and/or methane gas, which can lead to various gastrointestinal symptoms such as bloating, diarrhea, and/or flatulence. A disease known as lactose malabsorption may happen when the enzyme required to break down lactose, a sugar frequently found in dairy products, is absent. Because the enzyme is absent, bacteria that are normally prevalent in your digestive tract can produce hydrogen and/or methane gas, which can lead to various gastrointestinal symptoms such as bloating, diarrhea, and/or flatulence. Breath testing has become the recommended diagnosis plan for SIBO, IMO, and carbohydrate malabsorption disorders. CDI’s wide range of hydrogen and methane breath tests can be taken in the comfort of the patient’s home and are much less invasive than other diagnostic strategies including small bowel aspiration. 

“It is so important to drive awareness and education around GI disturbance, and it is always a push and pulls. The industry will always do what it can to drive awareness and education at the provider and the patient level. But we need patients educated, and we need both educating each other for this to work.” says Craig strasnick, President and CEO of Commonwealth diagnostics. Commonwealth Diagnostics International is located in Salem, Massachusetts, United States.